Markus Renschler - Jun 17, 2021 Form 3 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role
President and Chief Executive Officer Exhibit List: Exhibit 24 - Power of Attorney, Director
Signature
By: /s/ Andrew Gengos, Attorney-in-Fact
Stock symbol
CYT
Transactions as of
Jun 17, 2021
Transactions value $
$0
Form type
3
Date filed
6/17/2021, 09:13 PM
Next filing
Feb 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CYT Common Stock 842K Jun 17, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CYT Stock Option (Right to Buy) Jun 17, 2021 Common Stock 106K $1.02 Direct F2
holding CYT Stock Option (Right to Buy) Jun 17, 2021 Common Stock 63.4K $1.19 Direct F3
holding CYT Stock Option (Right to Buy) Jun 17, 2021 Common Stock 500K $7.09 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 125,226 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest.
F2 The option vests at a rate of 18,337 shares per month at the end of each successive one-month period beginning January 3, 2019, for 40 months, and at a rate of 14,670 shares per month at the end of the 41st month, at which point the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
F3 The option vested as to 1/48th of the underlying shares of common stock on February 1, 2020, and at the same rate at the end of each successive one-month period following such date until the fourth anniversary of such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
F4 The option will become exercisable as to 1/36th of the underlying shares of common stock at the end of each successive one-month period following the vesting commencement date, February 5, 2021, until the option is fully vested on the third anniversary of the vesting commencement date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date .

Remarks:

President and Chief Executive Officer Exhibit List: Exhibit 24 - Power of Attorney